PMN (ProMIS Neurosciences Inc.) Enterprise Value-to-Revenue Multiple

ProMIS (PMN) - corporate logo

ProMIS Neurosciences generates revenue based on the market launch of therapies for Alzheimer's and Parkinson's diseases. On GURU.Markets, the enterprise value-to-revenue ratio demonstrates market balance, where the 0.00 indicator determines the metric's magnitude. A stable geopolitical environment protects the company from sanctions, while innovative antibodies enable the targeted destruction of proteins to prevent brain aging.

PMN - ProMIS Neurosciences, Inc. Enterprise Value-to-Revenue Ratio over the range 11/23/2025 - 11/19/2026

PMN (ProMIS Neurosciences, Inc.): analytical breakdowns and indicator data

- stock value and consensus price forecast:
Fundamental company valuation:PMN (ProMIS)
Core merchandise of promisneurosciences.com

This indicator determines the business value, including debt and excluding cash, relative to annual sales volume to assess market overvaluation. An analysis of the EV/Sales ratio allows for the correlation of market capitalization with revenue, which for ProMIS Neurosciences (PMN) is justified by the uniqueness of its Alzheimer's disease combat platform and the extremely high barriers to entry in the FDA-supervised R&D sector.